Invictus MD Strategies Corp (TSXV: GENE) (OTCQX: IVITF) Holds All the Cards

0

Invictus MD Strategies Corp has been running up the charts in recent weeks as pot stocks one again heat up and light up the OTCBB.

On January 21 Invictus announced its intention to proceed with a consolidation of its issued and outstanding shares with a newly proposed reduced share consolidation ratio of one new share for every five old shares (1:5) in connection with its proposed listing on Nasdaq Stock Market LLC. The proposed reduced share consolidation ratio replaces the original consideration on the basis of one new share for seven old shares (1:7) The purpose of the consolidation is to increase the Company’s common share price to be in compliance with Nasdaq’s minimum share price listing requirement of USD $3.00 (CAD $3.98). Management believes this reduced ratio is sufficient to achieve Nasdaq’s minimum threshold. At Friday’s closing share price of CAD 1.06 (USD 0.80) on January 18, 2019, a 5:1 consolidation represents a new Company share valued at CAD 5.30 (US 3.99).

Invictus MD Strategies Corp (TSXV: GENE) (OTCQX: IVITF) (FRA: 8IS1) is a global cannabis company offering a selection of products under a wide range of lifestyle brands. The Company’s integrated sales approach is defined by five pillars of distribution including medical, adult-use, international, Licensed Producer to Licensed Producer and retail stores. The Company boast includes KISS music legend and business mogul Gene Simmons as Chief Evangelist Officer.

Invictus operates two cannabis production facilities fully licensed under ACMPR in Canada and a third awaiting approval, featuring 100,000 square feet of available grow space today with 200,000 expected by January 2019 and 1 million by end of 2020. Invictus offers a diversified product portfolio with over 69 Health Canada approved strains that will be sold under four lifestyle-inspired cannabis brands for recreational users: Dukes, Zooey, Sterling & Hunt, and Sinister. Invictus employs a multifaceted distribution strategy including medical, recreational, international and retail.

Invictus product portfolio includes 69 Health Canada approved strains that will be sold under four lifestyle-inspired cannabis brands for recreational users: Dukes, Zooey, Sterling & Hunt, and Sinister. Each brand has been crafted for a specific target audience and his or her lifestyle.

To Find out the inside Scoop on Invictus Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

Recently Invictus entered into a binding letter of intent to create a joint venture with Cannamerica Brands Corp. and CBDistribution Company Ltd. with the intention of acquiring hemp biomass for extraction into CBD isolate using purpose-built facilities for large scale CBD extraction. This follows the December 2018 Farm bill which recharacterized hemp from a schedule 1 drug with high potential for abuse to the lowest-level listed drug (schedule 5) which includes small doses of medicines such as codeine. This allows for mass hemp production in the United States that is federally legal and the ability to move hemp across state lines. Hemp is defined in the United States as cannabis with less than 0.3% THC. CBD, a non-psychoactive cannabinoid found in cannabis, has had a surge in popularity over the past couple of years based on its a huge range of potential health benefits and uses.

Invictus intends to enter into a definitive joint venture agreement on or before January 31, 2019. Each of the parties will receive a one-third share of the joint venture in exchange for their respective contribution: Invictus will contribute a line of credit (“LOC”) in the amount of $5 million CAD which will be used to acquire extraction equipment, build out infrastructure and fund working capital. The LOC will be secured by a general security agreement over the joint venture and will bear interest at a rate of 5% per annum.

On January 21 Invictus announced its subsidiary 0989561 B.C. Ltd. has received a sales license for its Delta location from Health Canada effective January 18, 2019, pursuant to the Access to Cannabis for Medical Purposes Regulations. The Delta Facility includes a cultivation, production and research facility, designed to highlight our capabilities as producers and breeders of superior cannabis strains.

George E. Kveton, President and CEO of Invictus stated:

“We are thrilled to have achieved another major milestone with our second sales license awarded by Health Canada. We have hit the ground running in 2019, remaining laser focused on our objective to bring new facilities online to cultivate unique strain varieties required for our medical and adult use recreational product portfolio.”

We have a Monster Pick Coming. Subscribe Right Now!

Currently trading at a $121 million market valuation Invictus is fully funded moving forward with $23 million in the treasury. The Company has virtually no debt and fast growing sales reporting $1,744,428 in revenues for the three months ended October 31, 2018 up from $600k for the same period last year. Invictus is on exciting cannabis play; the Company operates two cannabis production facilities fully licensed under ACMPR in Canada and a third awaiting approval, featuring 100,000 square feet of available grow space today with 200,000 expected by January 2019 and 1 million by end of 2020. We will be updating on Invictus when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with Invictus.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in Invictus either long or short and we have not been compensated for this article.

Share.

Leave A Reply

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.